Diagnostic value of BRAFV600E mutation analysis in fine needle aspiration for evaluation of thyroid nodules

다국어 초록 (Multilingual Abstract)

Objectives: Ultrasound-guided fine-needle aspiration (FNA) is routinely used in the evaluation of thyroid nodules. However, it has several pitfalls, as has been noted in nondiagnostic and indeterminate cases. This study aims to investigate the value of BRAFV600E mutation co-testing in FNA cytology. Method: A total of 310 patients underwent BRAFV600E mutation co-testing in FNA cytology on thyroid nodules between June 2013 and June 2014. Of the 310 patients, 69 patients who had undergone a surgery for thyroid nodules were included in this study. The presence of the BRAFV600E mutation was determined by allele-specific polymerase chain reaction amplification of exon 15 of the BRAF gene. Results: Of 69 cases, 33 (47.8%) were BRAFV600E mutation positive. The BRAFV600E mutation was not significantly associated with high-risk features such as tumor size, lymph node metastasis, and pathological stage. The respective diagnostic performance of FNA ( P = 0.02), BRAFV600E mutation ( P = 0.03), and ultrasonographic ( P = 0.00) findings was statistically significant. The sensitivity, specificity and positive predictive value of FNA was 64.9%, 83.3%, and 94.8%. The sensitivity, specificity and positive predictive value of BRAFV600E mutation was 56.1%, 91.7%, and 96.9% and the US features was 91.2%, 91.7%, and 98.1% respectively. However, sensitivity of FNA with BRAFV600E mutation (77.2%) was lower than FNA with US (92.9%) and combination all together (92.9%). Conclusion: In this study, we found that US features were the most useful in preoperative differential diagnosis of thyroid nodules. BRAFV600E mutation co-testing in FNA cytology was also useful for diagnosis of thyroid tumors.

참고문헌 (Reference)

1 안화영, "우리나라 갑상선암의 발생 현황 및 특징" 대한내과학회 77 (77): 537-542, 2009

2 이가희, "대한갑상선학회 갑상선결절 및 암 진료 권고안 개정안" 대한영상의학회 64 (64): 389-416, 2011

3 Koike E, "Ultrasonographic characteristics of thyroid nodules; prediction of malignancy" 136 : 334-337, 2001

4 Tan GH, "Thyroid incidentalomas: Management approaches to nonpalpable nodules discovered incidentally on thyroid imaging" 126 : 226-231, 1997

5 Ezzat S, "Thyroid incidentalomas. Prevalence by palpation and ultrasonography" 154 : 1838-1840, 1994

6 Vander JB, "The significance of nontoxic thyroid nodules: Final report of a 15-year study of the incidence of thyroid malignancy" 69 : 537-540, 1968

7 Hilger RA, "The Ras-Raf-MEK-ERK pathway in the treatment of cancer" 25 : 511-518, 2002

8 Cibas ES, "The Bethesda System for reporting thyroid cytopathology" 132 : 658-665, 2009

9 Kim SK, "Surgical results of thyroid nodules according to a management guideline based on the BRAF(V600E) mutation status" 96 : 658-664, 2011

10 American Thyroid Association (ATA) Guidelines Taskforce on Thyroid Nodules, "Revised American Thyroid Association management guidelines for patients with thyroid nodules and differentiated thyroid cancer" 19 : 1167-1214, 2009

11 Kim EK, "New sonographic criteria for recommending fine-needle aspiration biopsy of nonpalpable solid nodules of the thyroid" 178 : 687-691, 2002

12 Davies H, "Mutations of the BRAF gene in human cancer" 417 : 949-954, 2002

13 Mazzaferri EL, "Management of a solitary thyroid nodule" 328 : 553-559, 1993

14 Kwak JY, "How to combine ultrasound and cytological information in decision making about thyroid nodules" 19 : 1923-1931, 2009

15 Gharib H, "Fine needle aspiration biopsy of the thyroid: An appraisal" 118 : 282-289, 1993

16 DiLorenzo MM, "False-positive FNA due to highly sensitive BRAF assay" 20 : e8-e10, 2014

17 Nga ME, "Experience with standardized thyroid fine-needle aspiration reporting categories: follow-up data from 529 cases with "indeterminate" or "atypical" reports" 118 : 423-433, 2010

18 Hegedus L, "Clinical practice: the thyroid nodule" 351 : 1764-1771, 2004

19 Namba H, "Clinical implication of hot spot BRAF mutation, V599E, in papillary thyroid cancers" 88 : 4393-4397, 2003

20 서재영, "Can Ultrasound Be as a Surrogate Marker for Diagnosing a Papillary Thyroid Cancer? Comparison with BRAF Mutation Analysis" 연세대학교의과대학 55 (55): 871-878, 2014

21 Moon WJ, "Benign and malignant thyroid nodules: US differentiation-multicenter retrospective study" 247 : 762-770, 2008

22 Puxeddu E, "BRAF(V599E) mutation is the leading genetic event in adult sporadic papillary thyroid carcinomas" 89 : 2414-2420, 2004

23 Nikiforova MN, "BRAF mutations in thyroid tumors are restricted to papillary carcinomas and anaplastic or poorly differentiated carcinomas arising from papillary carcinomas" 88 : 5399-5404, 2003

24 Moon WJ, "BRAF mutation analysis and sonography as adjuncts to fine-needle aspiration cytology of papillary thyroid carcinoma: their relationships and roles" 198 : 668-674, 2012

25 Lipton RF, "Aspiration Biopsy and the Thyroid in Evaluation of Thyroid Dysfunction" 208 : 736-741, 1944

26 Bartolazzi A, "Application of an immunodiagnostic method for improving preoperative diagnosis of nodular thyroid lesions" 357 : 1644-1650, 2001